Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical Industry Clamps Down On Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

A conference was held on Jan. 22 to 25 in Guangzhou, China, to rally the pharmaceutical industry to crackdown on counterfeit drugs. According to the China Association for Technical Supervision Information, the national consortium for anti-counterfeit pharmaceuticals worked with authorities in 2007 to investigate more than 120 fake products and 30 infringement rights cases. Counterfeit drugs accounted for 60 percent of the cases investigated, while two-thirds were infringement cases. Counterfeiters have been duplicating and selling branded drugs despite China's crackdown on counterfeiting. As the activity causes business losses and poses a serious threat to public health, experts exhort the industry to assume more responsibilities and actions to deter such incidents. (Click here for more - Chinese Language)

You may also be interested in...

WHO Refines Approach For Listing Products In Health Emergencies

A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies. 

Pfizer Will Not Launch EU Adalimumab

Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.

New Arthroscopy Tubing Guidance Aims To Reduce Cross-Contamination

Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts